Offer
Provide additional details about the offer you're running.
This store requires javascript to be enabled for some features to work correctly.
Aging is often seen as a natural part of life, but a growing number of scientists and medical professionals argue that it should be classified as a disease. By viewing aging as a pathological process, we can better understand and address the underlying mechanisms that contribute to age-related decline and chronic diseases. This perspective shifts the focus toward treating and potentially reversing the effects of aging, ultimately improving the quality of life for older individuals.
At the heart of aging is a process called senescence. Cellular senescence refers to the state in which cells permanently stop dividing but do not die. This phenomenon can be triggered by various factors, including DNA damage, oxidative stress, and the shortening of telomeres—the protective caps at the ends of chromosomes that gradually erode with each cell division.
As cells enter senescence, they undergo significant changes:
The idea of classifying aging as a disease has gained traction among experts in the fields of geroscience and biotechnology. The World Health Organization (WHO) already lists aging under the ICD-11 (International Classification of Diseases) as a contributing factor to diseases, though it is not yet recognized as a standalone disease.
By acknowledging aging as a disease, we open the door to:
In fact, organizations like the American Federation for Aging Research (AFAR) and The Buck Institute for Research on Aging are actively studying ways to intervene in the biological processes of aging using senolytics, mTOR inhibitors, NAD+ boosters, and more.
At Gentera Center for Precision Medicine, we recognize that aging is not just a number—it's a biological process that can be measured, tracked, and addressed.
Our comprehensive approach includes:
As research progresses, the prospect of treating aging as a disease becomes more realistic. In 2023, the global anti-aging market was valued at over $68 billion, with continued growth projected as technology and public interest in longevity surge (Grand View Research, 2023). Senolytics, NAD+ boosters, and gene-editing techniques like CRISPR may soon become commonplace in clinical anti-aging protocols.
Ultimately, rethinking aging as a treatable, measurable condition empowers individuals to take control of their healthspan—not just their lifespan.